PharmaEngine, Inc. (TPEX:4162)

Market Cap	9.15B -25.3%
Revenue (ttm)	963.83M -62.1%
Net Income	422.55M -76.1%
EPS	2.93 -76.2%
Shares Out	143.68M
PE Ratio	21.74
Forward PE	n/a
Dividend	2.00 (3.14%)
Ex-Dividend Date	Aug 13, 2025

Volume	2,244,969
Open	61.20
Previous Close	61.00
Day's Range	61.20 - 65.60
52-Week Range	53.00 - 81.70
Beta	0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About PharmaEngine

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is also developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 45
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4162

Financial Performance

In 2025, PharmaEngine's revenue was 911.42 million, a decrease of -63.88% compared to the previous year's 2.52 billion. Earnings were 387.64 million, a decrease of -77.86%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 3, 2026

Data Sources Report a data error